Lo esencial para un diagnóstico certero de neumonía

http://sapiensmedicus.org/blog/2014/10/06/diagnostico-certero-de-neumonia/?utm_source=ReviveOldPost&utm_medium=social&utm_campaign=ReviveOldPost

EUROPEAN MEDICINES AGENCY (EMA) : inicio de la revisión de los corticoides inhalados en la EPOC

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Inhaled_corticosteroids_for_chronic_obstructive_pulmonary_disease/human_referral_prac_000050.jsp&mid=WC0b01ac05805c516f

The European Medicines Agency (EMA) has started a review of inhaled corticosteroid-containing medicines used to treat chronic obstructive pulmonary disease (COPD). COPD is a long-term inflammatory disease of the lungs in which the airways and air sacs in the lungs become damaged or blocked. Corticosteroids are widely used in the European Union (EU) to treat COPD and are usually taken by inhalation using an inhaler device.

The review of inhaled corticosteroid-containing medicines has been requested by the European Commission to evaluate the risk of pneumonia (inflammation of the lungs) when these medicines are used for COPD. The risk of pneumonia with these medicines is known and was first identified in 2007 when a study showed that patients treated with an inhaled corticosteroid, fluticasone, were at higher risk of developing pneumonia than those given placebo (dummy treatment)*. Since then, new studies of individual inhaled corticosteroids and combined study results (meta-analyses) on the class of inhaled corticosteroids have provided further data on the risk of pneumonia and it was considered necessary that a thorough review be performed to further characterise this risk.

EMA will now review all available data on the risk of pneumonia with inhaled corticosteroids for COPD and consider the need to update the existing prescribing advice across the EU.

Efficacy of 13-valent polysaccharide conjugate vaccine (PCV13) against Pneumococcal Pneumonia in Adults

http://www.nejm.org/doi/full/10.1056/NEJMoa1408544

CONCLUSIONS

Among older adults, PCV13 was effective in preventing vaccine-type pneumococcal, bacteremic, and nonbacteremic community-acquired pneumonia and vaccine-type invasive pneumococcal disease but not in preventing community-acquired pneumonia from any cause. 

Neumonías: Guía NICE de diagnóstico y tratamiento de las neumonías (de la comunidad y hospitalarias)

https://www.nice.org.uk/guidance/CG191

http://www.guidelines.co.uk/infection_nice_pneumonia#.VQk112SG_0g

Efecto de la vacuna antineumocócica 13-valente sobre la enfermedad neumocócica invasiva en niños y adultos de USA

http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(14)71081-3/abstract

PCV13 reduced invasive pneumococcal disease across all age groups when used routinely in children in the USA. These findings provide reassurance that, similar to PCV7, PCVs with additional serotypes can also prevent transmission to unvaccinated populations.

Guía 2015 de la BTS sobre neumonía adquirida en la comunidad

https://www.brit-thoracic.org.uk/guidelines-and-quality-standards/community-acquired-pneumonia-in-adults-guideline/annotated-bts-guideline-for-the-management-of-cap-in-adults-2015/

Recomendaciones de prescripción en neumonías. NICE

http://www.medicinesresources.nhs.uk/upload/documents/Health%20In%20Focus/NICEBites%20January%202015.pdf

El ojo de Markov : Riesgo de neumonías con el uso de glucocorticoides inhalados en EPOC

Acceder aquí

Se ha asociado un incremento de neumonías con el uso de glucocorticoides inhalados en pacientes con EPOC. Se resumen las evidencias de los estudios con fluticasona y budesonida, en monoterapia o en combinación. Por otro lado, se revisan las recomendaciones de uso de los glucocorticoides inhalados en EPOC.

Guía de la BTS para la neumonía adquirida en la comunidad en niños

en el siguiente enlace